The Hematology/Oncology Division is devoted to the delivery of high quality cancer care at MUSC's Hollings Cancer Center located at the Main Campus in downtown Charleston and at the affiliated Ralph H. Johnson VA Medical Center. Additionally, faculty members practice at the MUSC Health East Cooper facility in Mount Pleasant and the Specialty Care facility in North Charleston.
Founded in 1993 and named for former U.S. Senator and South Carolina Governor Ernest "Fritz" Hollings, the Hollings Cancer Center is the largest academic cancer center in South Carolina. It is the state's only National Cancer Institute (NCI)-designated cancer center and one of only 69 NCI centers in the U.S. In conjunction with the Hollings Cancer Center (HCC) and the Ralph H. Johnson VA Medical Center, the Division serves as a statewide referral center for solid tumor oncology, malignant and benign hematology, and bone marrow transplant. The Blood and Marrow Transplant (BMT) Program was the first established in South Carolina and is the state’s only certified National Marrow Donor Program for unrelated-donors. It is the only pediatric and cord blood transplant program and considered a pioneer in outpatient bone marrow transplants. The Division's faculty are heavily engaged in numerous multidisciplinary tumor boards and clinics at the HCC, ensuring that clinicians are able to collaborate across disciplines on patient care and allowing many patients with malignancies to see all of their physicians in one appointment.
The Division's faculty members are equally committed to research and lead efforts in the laboratory as well as in the conduct of clinical trials. Our comprehensive treatment protocols include an ever-expanding clinical trials portfolio offering studies for most types of cancer. As an NCI-Designated Cancer Center, Hollings offers clinical trials and therapies not available elsewhere in South Carolina.
The MUSC Hematology/Oncology Division has delivered outstanding cancer care to South Carolinians for more than thirty years. In 2015, Carolyn Britten, MD, was appointed as the Chief of the Division. Dr. Britten has a vision to greatly expand the clinical services and research within the division through doubling the numbers of clinicians committed to clinical and translational research, leading the development of partnerships with regional community-based cancer programs to extend the specialized oncology services of the division, and refining the training within the division’s fellowship program to yield a new generation of medical oncologists equipped to practice in an era of targeted therapies.
Carolyn D. Britten, M.D.